Prudential PLC Has $3.60 Million Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Key Points

• Prudential PLC increased its stake in Lantheus Holdings, Inc. by 168.7%, acquiring an additional 23,180 shares and bringing its total to 36,917 shares valued at approximately $3.6 million.
• Multiple institutional investors also expanded their holdings in Lantheus, with Janus Henderson Group PLC boosting its position by 72.7% to over 6.1 million shares valued at $554.6 million.
• Lantheus has faced challenges, recently reporting earnings of $1.57 per share, missing estimates, with a revenue decline of 4.1% compared to the previous year.

Prudential PLC raised its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 168.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 36,917 shares of the medical equipment provider's stock after acquiring an additional 23,180 shares during the quarter. Prudential PLC owned approximately 0.05% of Lantheus worth $3,603,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Signaturefd LLC lifted its position in shares of Lantheus by 36.5% in the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after buying an additional 116 shares during the last quarter. Hughes Financial Services LLC bought a new position in shares of Lantheus in the 1st quarter worth about $81,000. UMB Bank n.a. lifted its position in shares of Lantheus by 68.2% in the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock worth $92,000 after buying an additional 381 shares during the last quarter. Blue Trust Inc. lifted its position in shares of Lantheus by 117.7% in the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock worth $114,000 after buying an additional 633 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Lantheus by 29.3% in the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider's stock worth $128,000 after buying an additional 298 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the transaction, the director owned 318,650 shares of the company's stock, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 1.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. B. Riley reduced their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research report on Monday, June 23rd. William Blair reaffirmed a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Mizuho dropped their price objective on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating on the stock in a report on Thursday, August 7th. Finally, JMP Securities dropped their price objective on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a report on Thursday, August 7th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $105.50.

Lantheus Price Performance

Lantheus stock traded down $0.29 during trading hours on Friday, hitting $54.18. 1,221,713 shares of the company traded hands, compared to its average volume of 2,054,600. The firm has a market cap of $3.68 billion, a P/E ratio of 9.96 and a beta of 0.14. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The firm's 50-day simple moving average is $73.83 and its two-hundred day simple moving average is $85.43. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.08). The company had revenue of $378.05 million for the quarter, compared to analyst estimates of $389.69 million. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The firm's quarterly revenue was down 4.1% on a year-over-year basis. During the same period in the previous year, the business posted $1.80 EPS. As a group, analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.